Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on April 23, 2008. The filing addresses a material corporate governance event: the resignation of the Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statement data.
Material Changes
- Departure of Principal Officer: Mr. Bryce Chicoyne resigned as Chief Financial Officer, effective May 9, 2008.
- Interim Appointment: Susan Luscinski, currently the Chief Operating Officer, was appointed as the interim principal accounting and financial officer, effective May 9, 2008.
- Background: Ms. Luscinski has extensive tenure with the company, having previously served as CFO from 2001 to 2004 and in various finance roles since 1985.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational transition of the CFO role. A press release issued on April 25, 2008, regarding the resignation is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the effective date of the CFO transition (May 9, 2008).
- Review the attached press release (Exhibit 99.1) for additional context on the resignation.
- Confirm the qualifications and tenure of the interim CFO, Susan Luscinski.
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer.